|
J Biol Chem, Vol. 274, Issue 31, 22089-22094, July 30, 1999
Overactivation of Phospholipase C- 1 Renders Platelet-derived
Growth Factor -Receptor-expressing Cells Independent of the
Phosphatidylinositol 3-Kinase Pathway for Chemotaxis*
Lars
Rönnstrand ,
Agneta
Siegbahn§,
Charlotte
Rorsman,
Matilda
Johnell§,
Klaus
Hansen, and
Carl-Henrik
Heldin
From the Ludwig Institute for Cancer Research, Biomedical Centre,
Box 595, S-751 24 Uppsala, Sweden and the § Department of
Clinical Chemistry, University Hospital,
S-751 85 Uppsala, Sweden
 |
ABSTRACT |
We have previously shown that porcine aortic
endothelial cells expressing the Y934F platelet-derived growth factor
(PDGF) -receptor mutant respond to PDGF-BB in a chemotaxis assay at about 100-fold lower concentration than do wild-type PDGF
-receptor-expressing cells (Hansen, K., Johnell, M., Siegbahn, A.,
Rorsman, C., Engström, U., Wernstedt, C., Heldin, C.-H., and
Rönnstrand, L. (1996) EMBO J. 15, 5299-5313). Here
we show that the increased chemotaxis correlates with increased
activation of phospholipase C- 1 (PLC- 1), measured as
inositol-1,4,5-trisphosphate release. By two-dimensional phosphopeptide
mapping, the increase in phosphorylation of PLC- 1 was shown not to
be selective for any site, rather a general increase in phosphorylation
of PLC- 1 was seen. Specific inhibitors of protein kinase C,
bisindolylmaleimide (GF109203X), and phosphatidylinositol 3-kinase
(PI3-kinase), LY294002, did not affect the activation of PLC- 1. To
assess whether increased activation of PLC- 1 is the cause of the
hyperchemotactic behavior of the Y934F mutant cell line, we constructed
cell lines expressing either wild-type or a catalytically compromised
version of PLC- 1 under a tetracycline-inducible promoter.
Overexpression and concomitant increased activation of wild-type
PLC- 1 in response to PDGF-BB led to a hyperchemotactic behavior of
the cells, while the catalytically compromised PLC- 1 mutant had no
effect on PDGF-BB-induced chemotaxis. Furthermore, in cells expressing
normal levels of PLC- 1, chemotaxis was inhibited by LY294002. In
contrast, the increase in chemotactic response seen upon overexpression
of PLC- 1 was not inhibited by the PI3-kinase inhibitor LY294002.
These observations suggest the existence of two different pathways
which mediate PDGF-induced chemotaxis; depending on the cellular
context, the PI3-kinase pathway or the PLC- 1 pathway may dominate.
 |
INTRODUCTION |
Platelet-derived growth factor
(PDGF)1 stimulation of
responsive cells leads to induction of mitogenicity, chemotaxis, and actin reorganization (for review, see Ref. 1). PDGF is a family of
dimeric isoforms consisting of different combinations of
disulfide-bonded A- and B-chains. Thus, three isoforms of PDGF exist
with distinct binding characteristics toward the structurally related
PDGF - and -receptors. Binding of PDGF to its receptors leads to
dimerization of the receptors, an essential event in PDGF receptor
activation (2, 3). Dimerization leads to autophosphorylation on a
number of tyrosine residues in the intracellular part of the receptors, providing docking sites for a class of signal transduction molecules containing Src homology 2 (SH2) domains, including members of the Src
family of tyrosine kinases, phosphatidylinositol 3-kinase (PI3-kinase),
the GTPase activating protein of Ras (GAP), and phospholipase C- 1
(PLC- 1) (1).
In addition to undergoing autophosphorylation, the PDGF -receptor is
also phosphorylated on one specific tyrosine residue by members of the
Src family of tyrosine kinases. Autophosphorylation of the PDGF
-receptor in the juxtamembrane region leads to association, phosphorylation, and activation of c-Src (4) and to a subsequent phosphorylation by Src of Tyr934 in the receptor (5).
Mutation of Tyr934 to a phenylalanine residue and
expression of the mutant receptor in porcine aortic endothelial (PAE)
cells revealed an increased chemotactic response compared with cells
expressing the wild-type PDGF -receptor (5).
Blocking the association of the p85 subunit of PI3-kinase with the
PDGF -receptor, through mutation of Tyr740 and
Tyr751 to phenylalanine residues, led to a significant
reduction of the chemotactic response in response to PDGF-BB (6), which together with the observation that PDGF-induced chemotaxis is strongly
inhibited by the PI3-kinase inhibitor LY294002 (5) suggests a role for
PI3-kinase in mediating a chemotactic response to PDGF-BB.
The present study was undertaken to investigate the mechanisms behind
the increased chemotactic response in the Y934F mutant cell line. We
present data here that phosphorylation and activation of PLC- 1 are
considerably increased in the Y934F mutant receptor cell line.
Furthermore, by the use of cell lines expressing either wild-type or a
catalytically compromised mutant of PLC- 1 under the
tetracycline-inducible promoter, we could show that the lipase activity
of PLC- 1 is essential for the hyperchemotactic response and that
cells overexpressing PLC- 1 are independent of PI3-kinase for
PDGF-induced chemotaxis.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Precoated cellulose thin layer chromatography
plates were purchased from Merck (Darmstadt, Germany), modified
sequencing grade trypsin from Promega (Madison, WI).
Polyvinylpyrrolidone was from Aldrich (Steinheim, Germany).
Radionuclides were from Amersham Pharmacia Biotech (Buckinghamshire,
UK). The Hunter thin layer electrophoresis system was from C.B.S.
Scientific Co. (Del Mar, CA). LY294002 was from Biomol (Plymouth
Meeting, PA). Rabbit antiserum against PLC- 1 was generated by
immunizing rabbits with a peptide corresponding to the carboxyl
terminus of bovine PLC- 1 (7). An antiserum against the hemagglutinin
(HA) epitope tag was raised by immunizing a rabbit with the synthetic
peptide YPYDVPDYAGYPYDVPDYA conjugated to keyhole limpet hemocyanin (KLH).
Construction of Cell Lines Containing PLC- 1 under a
Tetracycline-inducible Promoter--
PAE cells expressing the PDGF
-receptor were stably transfected by electroporation with the
regulatory plasmid pUHD 172-1-neo (8). G-418-resistant clones were
screened by transient transfection with the luciferase reporter plasmid
pUHC 13-3 and tested for luciferase activity in the presence or
absence of doxycycline. Clones with low background expression of
luciferase and high inducibility in the presence of doxycycline were
chosen for transfection with the reporter plasmid pUHD 10-3 containing
either wild-type PLC- 1 or a lipase inactive PLC- 1 (H335F/H380F),
each containing a carboxyl-terminal HA-tag. Plasmids were
co-transfected with pPKGpuro, providing puromycin as selection marker.
Puromycin-resistant clones were screened by Western blotting for
expression of PLC- 1 in the presence or absence of doxycycline, using
either anti-PLC- 1 antiserum or an anti-HA-tag antiserum. The clone
used expressing wild-type PDGF -receptor and wild-type PLC- 1 is
thus denoted PAE/wt /PLC- 1wt, whereas the clone
expressing wild-type PDGF- -receptor and lipase compromised PLC- 1
is denoted PAE/wt /PLC- 1mut.
Assay for Release of Inositol Phosphates--
Six-well plates
with semi-confluent cultures of PAE/wt /PLC- 1wt or
PAE/wt /PLC- 1mut cells were incubated in the presence or absence of 20 ng/ml doxycycline for 24 h to induce protein expression, followed by overnight incubation with 2 µCi of
myo-[3H]inositol in 2 ml of inositol-free
Ham's F-12, containing 0.3% fetal calf serum. In cases where
bisindolylmaleimide or LY294002 were used, inhibitors were added to the
medium 60 min before stimulation with PDGF-BB. Assay for PDGF-induced
release of inositol phosphates was performed essentially according to
Eriksson et al. (9).
In vivo [32P]Orthophosphate Labeling of
Cells--
Cells were seeded at subconfluency 2 days before the
experiment and starved for 24 h in 0.2% fetal calf serum. Cells
were labeled with [32P]orthophosphate essentially as
described by Hansen et al. (5).
In Situ Trypsin Digestion, Two-dimensional Phosphopeptide
Mapping, and Phosphoamino Acid Analysis--
Phosphorylated proteins
were separated by SDS-polyacrylamide gel electrophoresis, using an 8%
gel and electrotransferred to nitrocellulose membrane (Hybond-C Extra,
Amersham Pharmacia Biotech). Samples were processed for tryptic
digestion, two-dimensional phosphopeptide mapping, and phosphoamino
acid analysis, as described by Blume-Jensen et al. (10).
Cell Motility Assay--
The chemotactic response of the
different cell lines was assayed by means of the leading front
technique in a modified Boyden chamber, as described previously (11).
In experiments where the effects of different inhibitors on the
motility response were tested, the cells were preincubated for 10 min
at 37 °C with the inhibitor at the indicated concentrations before
the experiment. The inhibitors were present throughout the experiment.
In cases when doxycycline-induced protein expression was used, cells
were incubated with 10 ng/ml doxycycline for 24 h before the
chemotaxis assay was performed. The chemotaxis assays were performed in
Ham's F-12, supplemented with 10% fetal calf serum and antibiotics.
Mitogenicity Assay--
PAE/wt /PLC- 1wt and
PAE/wt /PLC- 1mut cells were grown to confluency in
12-well plates and starved for 24 h in Ham's F-12 containing 1 mg/ml bovine serum albumin, in the presence or absence of 20 ng/ml
doxycycline to induce protein expression. Medium was changed to
the above medium containing 0.2 µg/ml [3H]thymidine and
varying concentrations of PDGF-BB. Cells were incubated for 24 h
at 37 °C, after which cells were fixed with trichloroacetic acid and
precipitated radioactivity was quantitated in a scintillation counter.
 |
RESULTS |
Analysis of PDGF-BB-stimulated Phosphorylation of PLC- 1--
We
have previously shown that cells expressing a PDGF -receptor with
Tyr934 mutated to a phenylalanine residue, show enhanced
chemotactic response compared with wild-type receptor-expressing cells
(5). It was also demonstrated that tyrosine phosphorylation of PLC- 1 in response to PDGF-BB was increased in cells expressing the Y934F mutant receptor. To assess whether the increase in phosphorylation was
selective for a particular tyrosine residue, and whether additional phosphorylation sites appeared in cells expressing the Y934F mutant, cells expressing the wild-type PDGF -receptor and the Y934F mutant receptor were labeled with [32P]orthophosphate. Following
stimulation with PDGF-BB, cells were lysed and PLC- 1
immunoprecipitated and processed for two-dimensional tryptic
phosphopeptide mapping. A general increase in the intensity of peptides
phosphorylated in response to PDGF-BB could be seen in the Y934F mutant
cell line, compared with cells expressing the wild-type PDGF
-receptor (Fig. 1). Several peptides
containing phosphotyrosine, as well as phosphoserine, appeared in
response to PDGF-BB stimulation (data not shown). No selective increase in the phosphorylation of any peptide, nor any new phosphopeptides, were seen in PLC- 1 from Y934F mutant cells.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 1.
Two-dimensional tryptic phosphopeptide maps
of PLC- 1 from wild-type PDGF
-receptor-expressing PAE cells or cells expressing
the Y934F mutant PDGF -receptor. Cells
were labeled with [32P]orthophosphate, stimulated with
PDGF-BB or left unstimulated, lysed, and immunoprecipitated with an
anti-PLC- 1 antiserum. Immunoprecipitated protein was separated by
SDS-gel electrophoresis, electrotransferred to Hybond-C Extra, and
digested in situ with trypsin. Phosphopeptides were
separated by electrophoresis at pH 1.9 in the first dimension and by
chromatography using isobutyric acid chromatography buffer in the
second dimension. A, PAE/wt cells without PDGF-BB
stimulation; B, PAE/wt cells with PDGF-BB stimulation;
C, PAE/Y934F cells without PDGF-BB stimulation; and
D, PAE/Y934F cells with PDGF-BB stimulation.
|
|
Independence of PKC and PI3-Kinase for PLC- 1
Activity--
Previously, we have shown that the increased chemotactic
response seen in the Y934F mutant receptor cell line could be inhibited by bisindolylmaleimide, a protein kinase C inhibitor, while leaving the
wild-type receptor-induced chemotactic response virtually unaffected.
In contrast, an inhibitor of PI3-kinase, LY294002, effectively
inhibited the chemotactic response seen in wild-type receptor-expressing cells, with little effect on the chemotactic response elicited by the Y934F mutant receptor (5). Therefore, we
investigated the effect of bisindolylmaleimide and LY294002 on PLC- 1
activity in the two cell lines. Cells were labeled with [3H]myoinositol, incubated with the respective
inhibitors, followed by stimulation with PDGF-BB and analysis of
produced IP3 (Fig. 2). The
inhibitor of protein kinase C, bisindolylmaleimide, showed no effect on
PLC- 1 activity, neither in wild-type receptor cells nor in the Y934F
mutant cells, whereas the PI3-kinase inhibitor LY294002 slightly
inhibited the PLC- 1 activity in both cell lines.

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 2.
Effect of LY294002 and GF109203X on PDGF-BB
stimulated inositol phosphate formation in wild-type PDGF
-receptor-expressing cells and in cells expressing
the Y934F mutant PDGF -receptor. Cells
were labeled with myo-[3H]inositol overnight
and stimulated with PDGF-BB. Released inositol phosphates were
determined. Cells were either treated with Me2SO
(control), 20 nM GF109203X (GF), or
2.8 µM LY294002 (LY)
|
|
Establishment of Stable Cell Lines Containing Wild-type or Dominant
Negative PLC- 1 under the Control of an Inducible Promoter--
In
order to investigate whether increased PLC- 1 activity causes
increased chemotaxis and thus could explain the hyperchemotactic phenotype of the Y934F mutant cell line, wild-type PDGF
-receptor-expressing cells were transfected with wild-type or
catalytically compromised HA-tagged human PLC- 1 under the control of
a tetracycline-inducible promoter. Cell clones were analyzed for
expression of PLC- 1 in the presence or absence of doxycycline.
Conditions were optimized so that the expression level of PLC- 1
would lead to a response in IP3 release after PDGF-BB
stimulation similar to that seen in the Y934F cells (Fig.
3). The clones used expressed a
negligible amount of HA-tagged protein in the absence of doxycycline,
while the protein expression was dramatically induced by doxycycline (Fig. 4).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 3.
Effect of overexpression of wild-type
PLC- 1 and a lipase-inactive mutant of
PLC- 1 on PDGF-BB-stimulated inositol
trisphosphate release. Cells induced to express either PLC- 1
construct by induction with 10 ng/ml doxycycline for 24 h, or
non-induced control, were labeled overnight with
myo-[3H]inositol in the presence or absence of
10 ng/ml doxycycline. Cells were subsequently stimulated with PDGF-BB
and analyzed for released inositol phosphates.
|
|

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 4.
Doxycycline induced expression of
PLC- 1 in the
PAE/wt /PLC- 1wt
and
PAE/wt /PLC- 1mut
cell lines. Cells were left untreated or induced to express
proteins with 10 ng/ml doxycycline for 24 h. Cell lysates
were separated by SDS-gel electrophoresis, followed by electrotransfer
to Immobilon-P filters. Filters were probed with either anti-PLC- 1
antiserum or anti-HA antiserum. IB, immunoblotting.
|
|
Overexpression of PLC- 1 Leads to a Hyperchemotactic Response to
PDGF-BB--
Expression of PLC- 1 was induced with doxycycline for
24 h. Cells were then assayed for chemotaxis by means of the
leading front technique in a modified Boyden chamber. In accordance
with the Y934F mutant cells, PDGF -receptor cells overexpressing
wild-type PLC- 1 responded to PDGF-BB with chemotaxis at
concentrations almost 100-fold lower compared with control cells
without induction of PLC- 1 expression (Fig.
5A). In contrast, cells
overexpressing a similar amount of a catalytically compromised version
of PLC- 1, in which two histidine residues (His335 and
His380) in the catalytic domain had been mutated to
phenylalanine residues, had exactly the same chemotactic response as
control cells (Fig. 5B).

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 5.
Effect of overexpression of
PLC- 1 on chemotaxis.
PAE/wt /PLC- 1wt or PAE/wt /PLC- 1mut
cells were treated with 10 ng/ml doxycycline for 24 h. Chemotaxis
toward PDGF-BB was assayed using the leading front technique in a
modified Boyden chamber. A, PAE/wt cells with (  )
or without (  ) doxycycline; PAE/wt /PLC- 1wt
cells with (  ) or without (  ) doxycycline; B,
PAE/wt /PLC- 1mut cells with (  ) or without
(  ) doxycycline.
|
|
The Chemotactic Response in Cells Overexpressing PLC- 1 Is
Resistant to Inhibition by LY294002--
Chemotaxis induced by PDGF-BB
in wild-type PDGF -receptor-expressing PAE cells is efficiently
inhibited by LY294002 (1). Similarly, chemotaxis was inhibited by
LY294002 in the absence of doxycycline in cells expressing wild-type
PLC- 1 under a tetracycline-inducible promoter. In contrast, when
cells were incubated with doxycycline to induce overexpression of
PLC- 1, the PI3-kinase inhibitor LY294002 had no effect on
PDGF-BB-induced chemotaxis (Fig.
6A). In contrast, when cells
expressing a dominant negative H335F/H380F mutant of PLC- 1 under a
tetracycline-inducible promoter were incubated with doxycycline, the
PI3-kinase inhibitor LY294002 effectively inhibited PDGF-BB-induced
chemotaxis (Fig. 6B). Thus, the lipase activity of PLC- 1
is necessary to allow cells to migrate in the presence of PI3-kinase
inhibitor.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 6.
Effect of inhibition of PI3-kinase on
chemotaxis in cells overexpressing PLC- 1.
PAE/wt /PLC- 1wt cells (A) or
PAE/wt /PLC- 1mut cells (B) were incubated
either in the presence (  ) or absence (  ) of 10 ng/ml
doxycycline for 24 h. Cells were incubated with varying
concentrations of LY294002 for 30 min at 37 °C prior to and during
the chemotaxis assay. Chemotaxis was induced by 10 ng/ml PDGF-BB.
|
|
Overexpression of Either Wild-type or Dominant Negative PLC- 1
Has No Effect on PDGF-BB-induced Mitogenicity in PDGF
-Receptor-expressing PAE Cells--
In order to assess the possible
role of PLC- 1 in mediating the mitogenic response to PDGF-BB, cells
were incubated with doxycycline for 24 h to induce overexpression
of either wild-type PLC- 1 or catalytically compromised PLC- 1,
followed by stimulation with varying concentrations of PDGF-BB and
incubation with [3H]thymidine for 24 h. However, no
effect was seen on PDGF-BB-induced [3H]thymidine
incorporation in cells expressing the wild-type or the catalytically
compromised PLC- 1 (Fig. 7,
A and B).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 7.
Effect of PLC- 1
overexpression on mitogenicity induced by PDGF-BB in wild-type
PDGF -receptor-expressing cells. Cells
were incubated in the presence or absence of doxycycline for 24 h,
followed by a 24-h incubation with [3H]thymidine in the
presence of varying concentrations of PDGF-BB, with or without
doxycycline present. Labeled DNA was precipitated by trichloroacetic
acid, and the incorporation of [3H]thymidine into DNA was
measured in a scintillation counter. A,
PAE/wt /PLC- 1wt cells with (  ) or without
(  ) doxycycline. B, PAE/wt /PLC- 1mut
cells with (  ) or without (  ) doxycycline. FBS, fetal
bovine serum.
|
|
 |
DISCUSSION |
We have previously shown that c-Src phosphorylates
Tyr934 in the second part of the kinase domain of the PDGF
-receptor (5). Cells transfected with a PDGF -receptor mutant
with Tyr934 replaced with a phenylalanine residue showed an
increased tyrosine phosphorylation of PLC- 1 and an enhanced
chemotactic response to PDGF-BB. We have now further shown that the
enhanced chemotaxis coincides with an increase in phosphorylation of
PLC- 1 on the same sites as those phosphorylated in response to
activation of the wild-type PDGF -receptor. Kim et al.
(12) have shown that phosphorylation of Tyr771 and
Tyr783 in PLC- 1 are essential for activation. No change
in the stoichiometry in phosphorylation of Tyr1021, the
primary association site for PLC- 1 in the PDGF -receptor, was
seen in cells expressing the Y934F mutant compared with cells expressing wild-type PDGF -receptor (data not shown). The reason for
the increased phosphorylation of PLC- 1 in cells expressing the Y934F
mutant PDGF -receptor is not known; it is possible that the receptor
kinase in the Y934F mutant has altered kinetics toward PLC- 1 as a
substrate. An additional possibility is that the increase in
phosphorylation of PLC- 1, at least in part, could be due to the
action of c-Src since it has been shown that c-Src is able to associate
with and phosphorylate PLC- 1 (13, 14). We found that the increased
phosphorylation of PLC- 1 correlated with an increase in
IP3 production (Fig. 2). The magnitude of IP3
production produced in the Y934F mutant cell line was about 3-fold
higher than in wild-type receptor-expressing cells. The difference in
response is not due to differences in receptor number or ligand
affinity between the cell lines, as indicated by Scatchard analyses of
PDGF-BB binding (1).
The importance of PLC- 1 in chemotactic signaling was pointed out by
Kundra et al. (15, 16). However, PAE cells expressing a PDGF
-receptor mutant, with the association site for PLC- 1 Tyr1021 mutated to a phenylalanine residue, showed
unaffected chemotaxis toward the ligand (6). On the other hand,
Wennström et al. (6) demonstrated that inhibition of
PI3-kinase with wortmannin in PAE cells expressing PDGF -receptors
led to inhibited chemotaxis. In contrast, Higaki et al. (17)
showed that, in vascular smooth muscle cells and Swiss 3T3 cells,
inhibition of PI3-kinase had no effect on chemotaxis. The chemotactic
response seen in the Y934F mutant cell line was, in contrast to the
response seen in the wild-type PDGF -receptor-expressing cells,
inhibited by bisindolylmaleimide, an inhibitor of protein kinase C, but
resistant to inhibition by the PI3-kinase inhibitor LY294002 (1). Here
we demonstrate that overexpression and enhanced activation of PLC- 1
also results in enhanced chemotactic response and that, under these
conditions, the PI3-kinase inhibitor LY294002 has no effect on the
chemotaxis induced by PDGF-BB. Taken together, these data suggest that
at least two pathways can mediate PDGF -receptor-induced chemotaxis, i.e. PI3-kinase and PLC- 1. It is possible that the
expression levels of PI3-kinase and PLC- 1, and their magnitude of
activation, determines which of these pathways will dominate.
Activation of PLC- 1 leads to production of two second messengers,
IP3 and diacylglycerol (DAG). Binding of IP3 to
receptors on the endoplasmic reticulum leads to release of calcium,
while DAG is an activator of the classical PKCs (18). Furthermore, DAG
has been implicated in stimulation of chemotaxis in lymphocytes (19,
20). We could not detect any effect of the PKC inhibitor bisindolylmaleimide on PLC- 1 activity, neither in wild-type cells, nor in the mutant cell line (Fig. 2). This is in contrast to findings by Ozawa et al. (21), who described feedback inhibition of
PLC- 1 by PKC- and PKC- in rat basophil RBL-2H3 cells. The
PI3-kinase inhibitor, LY294002, had a slight reducing effect on
PLC- 1 activity. This is consistent with findings that full
activation of PLC- 1 requires binding of
phosphatidylinositol-3,4,5-trisphosphate to its pleckstrin homology
(PH) domain (22, 23), an event that triggers translocation to the
membrane. In conclusion, the inhibitors bisindolylmaleimide and
LY294002 are likely to act downstream rather than upstream of PLC- 1
in the signaling pathways leading to chemotaxis.
The essential role of PLC- 1 in mammalian growth and development was
shown in mice with a targeted deletion of the PLC- 1 locus. This
deletion results in embryonic lethality at approximately day 9.0 of
embryonic development (24). The exact role of PLC- 1 in mitogenesis
is debated. Smith et al. (28) and Huang et al. (29) showed that microinjection of wild-type as well as the catalytically compromised mutant of PLC- 1 resulted in mitogenesis, suggesting that domains other than the catalytic domain might be
important for signaling. By microinjection of different domains of
PLC- 1 into NIH3T3 cells, Smith et al. (25) showed that
either the SH3 domain or the SH2 domains induced a partial response
that was restored when they were co-injected. The PH domain, however, did not induce DNA synthesis. In contrast, using the same cells, Huang
et al. (26) showed that deletion of the SH3 domain resulted in complete loss of mitogenic response. Using MDCK epithelial cells and
NIH3T3 cells, Wang et al. (27) could block PDGF-induced S-phase entry by microinjection of a polypeptide comprising the two SH2
domains and the SH3 domain of PLC- 1. Microinjection of DAG and
IP3 did not stimulate DNA synthesis by themselves but did
suppress the inhibitory effect of the SH2-SH2-SH3 polypeptide. These
observations suggest that both the SH2 and SH3 domains and the
catalytic activity of PLC- 1 are important for mediation of a
mitogenic response. In this report we did not observe any effect on
PDGF-BB-induced DNA replication upon overexpression of either wild-type
PLC- 1 or a catalytically compromised version of the lipase.
In summary, we have shown that either PI3-kinase or PLC- 1 are
required for induction of chemotaxis by the PDGF -receptor. Our
findings suggest that it is the expression levels of these individual
enzymes and the extent of their activation that determines which
pathway that mediates the chemotactic response in individual cell
lines. It is possible that the PLC- 1 and the PI3-kinase pathways are
both needed for the chemotactic response, or one can substitute for the
other given that it is expressed and activated at sufficient levels.
Cross-talk between the PLC- 1 pathway and PI3-kinase pathway is known
on several levels. Full activation of PLC- 1 was shown to require the
activity of PI3-kinase (22, 23, 28). Furthermore, Derman et
al. could show that products of PI3-kinase increased cell motility
through PKC (29). In addition to being activated by DAG, a product of
PLC- 1, PKC isoforms have been shown to be phosphorylated and
activated by PDK1, a downstream target of PI3-kinase (30).
Phosphorylation of the same conserved threonine residue in the
activation loop has previously been shown to be essential to render PKC
catalytically competent to autophosphorylate (31). Furthermore, PKC-
has been shown to be activated by both PI3-kinase and
PLC- 1-dependent pathways (32). However, one cannot
exclude the possibility that IP3 produced by PLC- 1,
leading to release of calcium from internal stores, plays a role in the increased chemotactic response seen upon PLC- 1 overexpression. An
important future goal will be to identify the common downstream signaling molecules that mediate the chemotactic response seen after
activation of PI3-kinase or PLC- 1.
 |
ACKNOWLEDGEMENT |
We thank Dr. Klaus Seedorf at the Hagedorn
Research Institute, Copenhagen, for cDNAs encoding wild-type
PLC- 1 and the lipase-deficient PLC- 1 mutant.
 |
FOOTNOTES |
*
This work was supported in part by a grant from the Nordic
Cancer Union, the Swedish Cancer Society, and the Axel and Margaret Ax:son Johnson Foundation.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.: +46 18 16 0406;
Fax: +46 18 16 04 20; E-mail: Lars.Ronnstrand@LICR.uu.se.
 |
ABBREVIATIONS |
The abbreviations used are:
PDGF, platelet-derived growth factor;
DAG, diacylglycerol;
HA, hemagglutinin
epitope;
IP3, inositol-1,4,5-trisphosphate;
PAE, porcine
aortic endothelial;
PH, pleckstrin homology;
PI3-kinase, phosphatidylinositol 3-kinase;
PLC- 1, phospholipase C- 1;
SH2, Src
homology 2;
SH3, Src homology 3;
PKC, protein kinase C.
 |
REFERENCES |
| 1.
|
Heldin, C.-H.,
Östman, A.,
and Rönnstrand, L.
(1998)
Biochim. Biophys. Acta
1378,
F79-F113[Medline]
[Order article via Infotrieve]
|
| 2.
|
Heldin, C.-H.
(1995)
Cell
80,
213-223[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Claesson-Welsh, L.
(1994)
J. Biol. Chem.
269,
32023-32026[Free Full Text]
|
| 4.
|
Kypta, R. M.,
Goldberg, Y.,
Ulug, E. T.,
and Courtneidge, S. A.
(1990)
Cell
62,
481-492[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Hansen, K.,
Johnell, M.,
Siegbahn, A.,
Rorsman, C.,
Engström, U.,
Wernstedt, C.,
Heldin, C.-H.,
and Rönnstrand, L.
(1996)
EMBO J.
15,
5299-5313[Medline]
[Order article via Infotrieve]
|
| 6.
|
Wennström, S.,
Siegbahn, A.,
Yokote, K.,
Arvidsson, A.-K.,
Heldin, C.-H.,
Mori, S.,
and Claesson-Welsh, L.
(1994)
Oncogene
9,
651-660[Medline]
[Order article via Infotrieve]
|
| 7.
|
Arteaga, C. L.,
Johnson, M. D.,
Todderud, G.,
Coffey, R. J.,
Carpenter, G.,
and Page, D. L.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
10435-10439[Abstract/Free Full Text]
|
| 8.
|
Gossen, M.,
Freundlieb, S.,
Bender, G.,
Müller, G.,
Hillen, W.,
and Bujard, H.
(1995)
Science
268,
1766-1769[Abstract/Free Full Text]
|
| 9.
|
Eriksson, A.,
Nånberg, E.,
Rönnstrand, L.,
Engström, U.,
Hellman, U.,
Rupp, E.,
Carpenter, G.,
Heldin, C.-H.,
and Claesson-Welsh, L.
(1995)
J. Biol. Chem.
270,
7773-7781[Abstract/Free Full Text]
|
| 10.
|
Blume-Jensen, P.,
Wernstedt, C.,
Heldin, C.-H.,
and Rönnstrand, L.
(1995)
J. Biol. Chem.
270,
14192-14200[Abstract/Free Full Text]
|
| 11.
|
Siegbahn, A.,
Hammacher, A.,
Westermark, B.,
and Heldin, C.-H.
(1990)
J. Clin. Invest.
85,
916-920
|
| 12.
|
Kim, H. K.,
Kim, J. W.,
Zilberstein, A.,
Margolis, B.,
Kim, J. G.,
Schlessinger, J.,
and Rhee, S. G.
(1991)
Cell
65,
435-441[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Liao, F.,
Shin, H. S.,
and Rhee, S. G.
(1993)
Biochem. Biophys. Res. Commun.
191,
1028-1033[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Nakanishi, O.,
Shibasaki, F.,
Hidaka, M.,
Homma, Y.,
and Takenawa, T.
(1993)
J. Biol. Chem.
268,
10754-10759[Abstract/Free Full Text]
|
| 15.
|
Kundra, V.,
Escobedo, J. A.,
Kazlauskas, A.,
Kim, H. K.,
Rhee, S. G.,
Williams, L. T.,
and Zetter, B. R.
(1994)
Nature
367,
474-476[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Kundra, V.,
Soker, S.,
and Zetter, B. R.
(1994)
Oncogene
9,
1429-1435[Medline]
[Order article via Infotrieve]
|
| 17.
|
Higaki, M.,
Sakaue, H.,
Ogawa, W.,
Kasuga, M.,
and Shimokado, K.
(1996)
J. Biol. Chem.
271,
29342-29346[Abstract/Free Full Text]
|
| 18.
|
Dekker, L. V.,
and Parker, P. J.
(1994)
Trends. Biochem. Sci.
19,
73-77[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Boonen, G. J. J. C.,
de Koster, B. M.,
VanSteveninck, J.,
and Elferink, J. G. R.
(1993)
Biochim. Biophys. Acta
1178,
97-102[Medline]
[Order article via Infotrieve]
|
| 20.
|
Wright, T. M.,
Hoffman, R. D.,
Nishijima, J.,
Jakoi, L.,
Snyderman, R.,
and Shin, H. S.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
1869-1873[Abstract/Free Full Text]
|
| 21.
|
Ozawa, K.,
Yamada, K.,
Kazanietz, M. G.,
Blumberg, P. M.,
and Beaven, M. A.
(1993)
J. Biol. Chem.
268,
2280-2283[Abstract/Free Full Text]
|
| 22.
|
Falasca, M.,
Logan, S. K.,
Lehto, V. P.,
Baccante, G.,
Lemmon, M. A.,
and Schlessinger, J.
(1998)
EMBO J.
17,
414-422[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Rameh, L. E.,
Rhee, S. G.,
Spokes, K.,
Kazlauskas, A.,
Cantley, L. C.,
and Cantley, L. G.
(1998)
J. Biol. Chem.
273,
23750-23757[Abstract/Free Full Text]
|
| 24.
|
Ji, Q.-S.,
Winnier, G. E.,
Niswender, K. D.,
Horstman, D.,
Wisdom, R.,
Magnuson, M. A.,
and Carpenter, G.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
2999-3003[Abstract/Free Full Text]
|
| 25.
|
Smith, M. R.,
Liu, Y.-l.,
Kim, S. R.,
Bae, Y. S.,
Kim, C. G.,
Kwon, K.-S.,
Rhee, S. G.,
and Kung, H.-f.
(1996)
Biochem. Biophys. Res. Commun.
222,
186-193[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Huang, P. S.,
Davis, L.,
Huber, H.,
Goodhart, P. J.,
Wegrzyn, R. E.,
Oliff, A.,
and Heimbrook, D. C.
(1995)
FEBS Lett.
358,
287-292[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Wang, Z.,
Glück, S.,
Zhang, L.,
and Moran, M. F.
(1998)
Mol. Cell. Biol.
18,
590-597[Abstract/Free Full Text]
|
| 28.
|
Bae, Y. S.,
Cantley, L. G.,
Chen, C. S.,
Kim, S. R.,
Kwon, K. S.,
and Rhee, S. G.
(1998)
J. Biol. Chem.
273,
4465-4469[Abstract/Free Full Text]
|
| 29.
|
Derman, M. P.,
Toker, A.,
Hartwig, J. H.,
Spokes, K.,
Falck, J. R.,
Chen, C.-S.,
Cantley, L. C.,
and Cantley, L. G.
(1997)
J. Biol. Chem.
272,
6465-6470[Abstract/Free Full Text]
|
| 30.
|
Good, J. A. L.,
Ziegler, W. H.,
Parekh, D. B.,
Alessi, D. R.,
Cohen, P.,
and Parker, P. J.
(1998)
Science
281,
2042-2045[Abstract/Free Full Text]
|
| 31.
|
Keranen, L. M.,
Dutil, E. M.,
and Newton, A. C.
(1995)
Curr. Biol.
5,
1394-1403[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Moriya, S.,
Kazlauskas, A.,
Akimoto, K.,
Hirai, S.-i.,
Mizuno, K.,
Takenawa, T.,
Fukui, Y.,
Watanabe, Y.,
Ozaki, S.,
and Ohno, S.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
151-155[Abstract/Free Full Text]
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. Hellberg, C. Schmees, S. Karlsson, A. Ahgren, and C.-H. Heldin
Activation of Protein Kinase C {alpha} Is Necessary for Sorting the PDGF {beta}-Receptor to Rab4a-dependent Recycling
Mol. Biol. Cell,
June 15, 2009;
20(12):
2856 - 2863.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. C. Weiger, C.-C. Wang, M. Krajcovic, A. T. Melvin, J. J. Rhoden, and J. M. Haugh
Spontaneous phosphoinositide 3-kinase signaling dynamics drive spreading and random migration of fibroblasts
J. Cell Sci.,
February 1, 2009;
122(3):
313 - 323.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. P. Jones and M. Katan
Role of Phospholipase C{gamma}1 in Cell Spreading Requires Association with a {beta}-Pix/GIT1-Containing Complex, Leading to Activation of Cdc42 and Rac1
Mol. Cell. Biol.,
August 15, 2007;
27(16):
5790 - 5805.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Zhou, S. J. Martinez, M. Haber, E. V. Jones, D. Bouvier, G. Doucet, A. T. Corera, E. A. Fon, A. H. Zisch, and K. K. Murai
EphA4 Signaling Regulates Phospholipase C{gamma}1 Activation, Cofilin Membrane Association, and Dendritic Spine Morphology
J. Neurosci.,
May 9, 2007;
27(19):
5127 - 5138.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. P. Jones, J. Peak, S. Brader, S. A. Eccles, and M. Katan
PLC{gamma}1 is essential for early events in integrin signalling required for cell motility
J. Cell Sci.,
June 15, 2005;
118(12):
2695 - 2706.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. C.Y. Leung, A. Lawrie, S. Demaries, H. Massaeli, A. Burry, S. Yablonsky, J. M. Sarjeant, E. Fera, E. Rassart, J. G. Pickering, et al.
Apolipoprotein D and Platelet-Derived Growth Factor-BB Synergism Mediates Vascular Smooth Muscle Cell Migration
Circ. Res.,
July 23, 2004;
95(2):
179 - 186.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Nagel, E. Tahinci, K. Symes, and R. Winklbauer
Guidance of mesoderm cell migration in the Xenopus gastrula requires PDGF signaling
Development,
June 1, 2004;
131(11):
2727 - 2736.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Kallin, J.-B. Demoulin, K. Nishida, T. Hirano, L. Ronnstrand, and C.-H. Heldin
Gab1 Contributes to Cytoskeletal Reorganization and Chemotaxis in Response to Platelet-derived Growth Factor
J. Biol. Chem.,
April 23, 2004;
279(17):
17897 - 17904.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Plattner, A. J. Koleske, A. Kazlauskas, and A. M. Pendergast
Bidirectional Signaling Links the Abelson Kinases to the Platelet-Derived Growth Factor Receptor
Mol. Cell. Biol.,
March 15, 2004;
24(6):
2573 - 2583.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Persson, C. Savenhed, A. Bourdeau, M. L. Tremblay, B. Markova, F. D. Bohmer, F. G. Haj, B. G. Neel, A. Elson, C.-H. Heldin, et al.
Site-Selective Regulation of Platelet-Derived Growth Factor {beta} Receptor Tyrosine Phosphorylation by T-Cell Protein Tyrosine Phosphatase
Mol. Cell. Biol.,
March 1, 2004;
24(5):
2190 - 2201.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Bergqvist, S. Sundstrom, L. Y. Dimberg, E. Gylfe, and M. G. Masucci
The Hepatitis C Virus Core Protein Modulates T Cell Responses by Inducing Spontaneous and Altering T-cell Receptor-triggered Ca2+ Oscillations
J. Biol. Chem.,
May 23, 2003;
278(21):
18877 - 18883.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Katakai, T. Hara, M. Sugai, H. Gonda, Y. Nambu, E. Matsuda, Y. Agata, and A. Shimizu
Chemokine-independent Preference for T-helper-1 Cells in Transendothelial Migration
J. Biol. Chem.,
December 20, 2002;
277(52):
50948 - 50958.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Kanazawa, K. Ohsawa, Y. Sasaki, S. Kohsaka, and Y. Imai
Macrophage/Microglia-specific Protein Iba1 Enhances Membrane Ruffling and Rac Activation via Phospholipase C-gamma -dependent Pathway
J. Biol. Chem.,
May 24, 2002;
277(22):
20026 - 20032.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Paulhe, C. Racaud-Sultan, A. Ragab, C. Albiges-Rizo, H. Chap, N. Iberg, O. Morand, and B. Perret
Differential Regulation of Phosphoinositide Metabolism by alpha Vbeta 3 and alpha Vbeta 5 Integrins upon Smooth Muscle Cell Migration
J. Biol. Chem.,
November 2, 2001;
276(45):
41832 - 41840.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. EMAMI, N. LE FLOCH, E. BRUYNEEL, L. THIM, F. MAY, B. WESTLEY, M.-C. RIO, M. MAREEL, and C. GESPACH
Induction of scattering and cellular invasion by trefoil peptides in src- and RhoA-transformed kidney and colonic epithelial cells
FASEB J,
February 1, 2001;
15(2):
351 - 361.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Siegbahn, M. Johnell, C. Rorsman, M. Ezban, C.-H. Heldin, and L. Ronnstrand
Binding of factor VIIa to tissue factor on human fibroblasts leads to activation of phospholipase C and enhanced PDGF-BB-stimulated chemotaxis
Blood,
November 15, 2000;
96(10):
3452 - 3458.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Amyere, B. Payrastre, U. Krause, P. V. D. Smissen, A. Veithen, and P. J. Courtoy
Constitutive Macropinocytosis in Oncogene-transformed Fibroblasts Depends on Sequential Permanent Activation of Phosphoinositide 3-Kinase and Phospholipase C
Mol. Biol. Cell,
October 1, 2000;
11(10):
3453 - 3467.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
M. Kovalenko, K. Denner, J. Sandstrom, C. Persson, S. GroB, E. Jandt, R. Vilella, F. Bohmer, and A. Ostman
Site-selective Dephosphorylation of the Platelet-derived Growth Factor beta -Receptor by the Receptor-like Protein-tyrosine Phosphatase DEP-1
J. Biol. Chem.,
May 26, 2000;
275(21):
16219 - 16226.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1999 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|